Expression of human epithelial growth factor receptor 2 in advanced lung adenocarcinoma with epithelial growth factor receptor mutation and its significance
10.3760/cma.j.issn.1006-9801.2017.05.004
- VernacularTitle:人表皮生长因子受体2在表皮生长因子受体突变中晚期肺腺癌中的表达及其意义
- Author:
Wei WEI
;
Huazhen WU
;
Zhiming LUO
;
Kaiheng LI
;
Jiang MENG
;
Huaping ZHOU
;
Xingyang XUE
- Keywords:
Lung neoplasms;
Adenocarcinoma;
Receptor,epithelial growth factor;
Mutation;
Immunohistochemistry;
Human epidermal growth factor receptor 2
- From:
Cancer Research and Clinic
2017;29(5):304-307
- CountryChina
- Language:Chinese
-
Abstract:
Objective To detect the expression of human epithelial growth factor receptor 2 (HER-2) in advanced lung adenocarcinoma with epithelial growth factor receptor (EGFR) mutation, and to explore the potential of HER-2 as a therapeutic target for drug resistance in patients with EGFR mutations. Methods HER-2 is commonly expressed in the advanced lung adenocarcinoma with EGFR mutations, mainly in the cell membrane. Results The overexpression rate of HER-2 protein in tissues of advanced lung adenocarcinoma with EGFR mutations was 33.3%(28/84). The overexpression rate of HER-2 protein in patients>50 years of age was 40.3%(27/67), which was significantly higher than that of patients ≤50 years of age [5.9 % (1/17)], the difference was statistically significant (χ2=7.227, P=0.007). The overexpression rate of HER-2 protein in patients with high pathological differentiation [44.4 % (8/18)] was higher than that in patients with poor pathological differentiation [30.3%(20/66)], but the difference was not statistically significant (χ2=1.273, P=0.259). The overexpression of HER-2 protein in patients with EGFR 21 exon mutation [40.5 % (17/42)] was significantly higher than that of EGFR19 exon mutation [25.0%(10/40)], but the difference was not statistical significance (χ2=2.222, P=0.136). Conclusions The overexpression rate of HER-2 protein in advanced lung adenocarcinoma patients with EGFR mutation is high, which is related to the age and tumor differentiation. HER-2 is expected to be a potential therapeutic target for drug resistance patients with EGFR mutations.
